Increased gene expression of urotensin II-related peptide in the hearts of rats with congestive heart failure

Peptides

Volumn 29, Issue 5, 2008, Pages 801-808

  Nakayama, Takashi ^a   Hirose, Takuo ^a   Totsune, Kazuhito ^a,b   Mori, Nobuyoshi ^c   Maruyama, Yutaka ^b   Maejima, Takahiro ^a   Minagawa, Kana ^a   Morimoto, Ryo ^a   Asayama, Kei ^b   Kikuya, Masahiro ^a   Ohkubo, Takayoshi ^a,b   Hashimoto, Junichiro ^a,b   Kohzuki, Masahiro ^c   Takahashi, Kazuhiro ^b,c   Imai, Yutaka ^a,b  

^a TOHOKU UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^b TOHOKU UNIVERSITY   (Japan)

^c TOHOKU UNIVERSITY SCHOOL OF MEDICINE   (Japan)

Author keywords

GPR14; Heart failure; Immunocytochemistry; RT PCR; Urotensin II; Urotensin II related peptide

Indexed keywords

MESSENGER RNA; NEUROPEPTIDE; UNCLASSIFIED DRUG; UROTENSIN II; UROTENSIN II RELATED PEPTIDE;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BLOOD VESSEL; CONGESTIVE HEART FAILURE; CONTROLLED STUDY; CORONARY ARTERY LIGATION; GENE EXPRESSION; HEART ATRIUM; HEART MUSCLE; HEART RIGHT VENTRICLE; IMMUNOCYTOCHEMISTRY; IMMUNOHISTOCHEMISTRY; KIDNEY; MALE; NONHUMAN; NUCLEOTIDE SEQUENCE; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ANIMALS; ENDOTHELIN-1; GENE EXPRESSION; HEART FAILURE; MALE; MYOCARDIUM; PEPTIDE HORMONES; RATS; RATS, INBRED WKY; RECEPTORS, G-PROTEIN-COUPLED; UROTENSINS;

RATTUS;

EID: 42049110771     PISSN: 01969781     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.peptides.2007.12.018     Document Type: Article

References (32)

1. Ames R.S., Sarau H.M., Chambers J.K., Willette R.N., Aiyar N.V., Romanic A.M., et al. Human urotensin-II is a potent vasoconstrictor and agonist for the orphan receptor GPR14. Nature 401 (1999) 282-286
2. Bottrill F.E., Douglas S.A., Hiley C.R., and White R. Human urotensin-II is an endothelium-dependent vasodilator in rat small arteries. Br J Pharmacol 130 (2000) 1865-1870
3. Chatenet D., Dubessy C., Leprince J., Boularan C., Carlier L., Segalas-Milazzo I., et al. Structure-activity relationships and structural conformation of a novel urotensin II-related peptide. Peptides 25 (2004) 1819-1830
4. Cheung B.M., Leung R., Man Y.B., and Wong L.Y. Plasma concentration of urotensin II is raised in hypertension. J Hypertens 22 (2004) 1341-1344
5. Coulouarn Y., Lihrmann I., Jegou S., Anouar Y., Tostivint H., Beauvillain J.C., et al. Cloning of the cDNA encoding the urotensin II precursor in frog and human reveals intense expression of the urotensin II gene in motoneurons of the spinal cord. Proc Natl Acad Sci USA 95 (1998) 15803-15808
6. Douglas S.A., Tayara L., Ohlstein E.H., Halawa N., and Giaid A. Congestive heart failure and expression of myocardial urotensin II. Lancet 359 (2002) 1990-1997
7. Johns D.G., Ao Z., Naselsky D., Herold C.L., Maniscalco K., Sarov-Blat L., et al. Urotensin-II-mediated cardiomyocyte hypertrophy: effect of receptor antagonism and role of inflammatory mediators. Naunyn Schmiedebergs Arch Pharmacol 370 (2004) 238-250
8. Mori M., and Fujino M. Urotensin II-related peptide, the endogenous ligand for the urotensin II receptor in the rat brain. Peptides 25 (2004) 1815-8181 [Review]
9. Morimoto R, Satoh F, Murakami O, Totsune K, Arai Y, Suzuki T, et al. Immunolocalization of urotensin II and its receptor in human adrenal tumors and attached non-neoplastic adrenal tissues. Peptides, 2007, Jul 4, [Epub ahead of print] PMID: 17686550 (this issue).
10. Ng L.L., Loke I., O'Brien R.J., Squire I.B., and Davies J.E. Plasma urotensin in human systolic heart failure. Circulation 106 (2002) 2877-2880
11. Prosser H.C., Leprince J., Vaudry H., Richards A.M., Forster M.E., and Pemberton C.J. Cardiovascular effects of native and non-native urotensin II and urotensin II-related peptide on rat and salmon hearts. Peptides 27 (2006) 3261-3268
12. Richards A.M., Nicholls M.G., Lainchbury J.G., Fisher S., and Yandle T.G. Plasma urotensin II in heart failure. Lancet 360 (2002) 545-546
13. Russell F.D., Molenaar P., and O'Brien D.M. Cardiostimulant effects of urotensin-II in human heart in vitro. Br J Pharmacol 132 (2001) 5-9
14. Sakai S., Miyauchi T., Kobayashi M., Yamaguchi I., Goto K., and Sugishita Y. Inhibition of myocardial endothelin pathway improves long-term survival in heart failure. Nature 384 (1996) 353-355
15. Satoh F., Takahashi K., Murakami O., Totsune K., Sone M., Ohneda M., et al. Immunocytochemical localization of adrenomedullin-like immunoreactivity in the human hypothalamus and the adrenal gland. Neurosci Lett 203 (1996) 207-210
16. Sauzeau V., Le Mellionnec E., Bertoglio J., Scalbert E., Pacaud P., and Loirand G. Human urotensin II-induced contraction and arterial smooth muscle cell proliferation are mediated by RhoA and Rho-kinase. Circ Res 88 (2001) 1102-1104
17. Shi L., Ding W., Li D., Wang Z., Jiang H., Zhang J., et al. Proliferation and anti-apoptotic effects of human urotensin II on human endothelial cells. Atherosclerosis 188 (2006) 260-264
18. Song W., Abdel-Razik A.E., Lu W., Ao Z., Johns D.G., Douglas S.A., et al. Urotensin II and renal function in the rat. Kidney Int 69 (2006) 1360-1368
19. Stirrat A., Gallagher M., Douglas S.A., Ohlstein E.H., Berry C., Kirk A., et al. Potent vasodilator responses to human urotensin-II in human pulmonary and abdominal resistance arteries. Am J Physiol Heart Circ Physiol 280 (2001) H925-H928
20. Sugo T., Murakami Y., Shimomura Y., Harada M., Abe M., Ishibashi Y., et al. Identification of urotensin II-related peptide as the urotensin II-immunoreactive molecule in the rat brain. Biochem Biophys Res Commun 310 (2003) 860-868
21. Takahashi K., Totsune K., Murakami O., Arihara Z., Noshiro T., Hayashi Y., et al. Expression of urotensin II and its receptor in adrenal tumors and stimulation of proliferation of cultured tumor cells by urotensin II. Peptides 24 (2003) 301-306
22. Takahashi K., Totsune K., Murakami O., Saruta M., Nakabayashi M., Suzuki T., et al. Expression of urocortin III/stresscopin in human heart and kidney. J Clin Endocrinol Metab 89 (2004) 1897-1903
23. Takahashi K., Totsune K., Murakami O., and Shibahara S. Expression of urotensin II and urotensin II receptor mRNAs in various human tumor cell lines and secretion of urotensin II-like immunoreactivity by SW-13 adrenocortical carcinoma cells. Peptides 22 (2001) 1175-1179
24. Totsune K., Mackenzie H.S., Totsune H., Troy J.L., Lytton J., and Brenner B.M. Upregulation of atrial natriuretic peptide gene expression in remnant kidney of rats with reduced renal mass. J Am Soc Nephrol 9 (1998) 1613-1619
25. Totsune K., Takahashi K., Arihara Z., Sone M., Ito S., and Murakami O. Increased plasma urotensin II levels in patients with diabetes mellitus. Clin Sci 104 (2003) 1-5
26. Totsune K., Takahashi K., Arihara Z., Sone M., Murakami O., Ito S., et al. Elevated plasma levels of immunoreactive urotensin II and its increased urinary excretion in patients with Type 2 diabetes mellitus: association with progress of diabetic nephropathy. Peptides 25 (2004) 1809-1814
27. Totsune K., Takahashi K., Arihara Z., Sone M., Satoh F., Ito S., et al. Role of urotensin II in patients on dialysis. Lancet 358 (2001) 810-811
28. Totsune K., Takahashi K., Mackenzie H.S., Arihara Z., Satoh F., Sone M., et al. Adrenomedullin and its receptor complexes in remnant kidneys of rats with renal mass ablation: decreased expression of calcitonin receptor-like receptor and receptor-activity modifying protein-3. Peptides 22 (2001) 1933-1937
29. Totsune K., Takahashi K., Mackenzie H.S., Murakami O., Arihara Z., Sone M., et al. Increased gene expression of adrenomedullin and adrenomedullin-receptor complexes, receptor-activity modifying protein (RAMP)2 and calcitonin-receptor-like receptor (CRLR) in the hearts of rats with congestive heart failure. Clin Sci (Lond) 99 (2000) 541-546
30. Watanabe T., Pakala R., Katagiri T., and Benedict C.R. Synergistic effect of urotensin II with mildly oxidized LDL on DNA synthesis in vascular smooth muscle cells. Circulation 104 (2001) 16-18
31. Yoshimura M., Yasue H., Tanaka H., Kikuta K., Sumida H., Kato H., et al. Responses of plasma concentrations of A type natriuretic peptide and B type natriuretic peptide to alacepril, an angiotensin-converting enzyme inhibitor, in patients with congestive heart failure. Br Heart J 72 (1994) 528-533
32. Zhang P.L., Mackenzie H.S., Totsune K., Troy J.L., and Brenner B.M. Renal effects of high-dose natriuretic peptide receptor blockade in rats with congestive heart failure. Circ Res 77 (1995) 1240-1245